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Maternal physiological hypercholesterolemia occurs during pregnancy, ensuring normal fetal development. In some cases,
the maternal plasma cholesterol level increases to above this physiological range, leading to maternal supraphysiological
hypercholesterolemia (MSPH). This condition results in endothelial dysfunction and atherosclerosis in the fetal and placental
vasculature. The fetal and placental endothelial dysfunction is related to alterations in the L-arginine/nitric oxide (NO) pathway
and the arginase/urea pathway and results in reduced NO production. The level of tetrahydrobiopterin (BH
4
), a cofactor for
endothelial NO synthase (eNOS), is reduced in nonpregnant women who have hypercholesterolemia, which favors the generation
of the superoxide anion rather than NO (from eNOS), causing endothelial dysfunction. However, it is unknown whether MSPH
is associated with changes in the level or metabolism of BH
4
; as a result, eNOS function is not well understood. This review
summarizes the available information on the potential link between MSPH and BH
4
in causing human fetoplacental vascular
endothelial dysfunction, whichmay be crucial for understanding the deleterious effects ofMSPH on fetal growth and development.
1. Introduction
Hypercholesterolemia is considered one of the most impor-
tant risk factors for the development of cardiovascular disease
(Adult Treatment Panel ATP III) [1, 2]. Pregnancy is a physio-
logical process that can involve the development of maternal
pathologies, such as preeclampsia, gestational diabetes mel-
litus (GDM), and metabolic disorders, including maternal
pregestational obesity, supraphysiological gestational weight
gain (spGWG) [3, 4], and hypercholesterolemia [5, 6]. These
alterations may compromise the health of the mother and/or
the fetus [5–7]. In normal pregnancies, the mother exhibits a
physiological (i.e., normal) increase (30–50%) in the plasma
total cholesterol (TCh) level in a process that is referred
to as maternal physiological hypercholesterolemia (MPH)
[5, 6, 8]. However, in some cases, for mostly unknown
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reasons, the TCh level is elevated far beyond the physiological
range, which is referred to as maternal supraphysiological
hypercholesterolemia (MSPH) [5, 6, 9]. Although studies
have shown the potential adverse effects of MSPH on the
early development of atherosclerosis [10, 11] and endothelial
dysfunction in the fetoplacental vasculature [5, 6], the global
prevalence of MSPH remains unknown [12].
Endothelial cells synthetize nitric oxide (NO), a potent
vasodilator that is generated by NO synthases (NOS; i.e.,
the L-arginine/NO pathway), following the oxidation of L-
arginine in a process that depends on the bioactivity of
several cofactors, including tetrahydrobiopterin (BH
4
) [13–
15]. In pregnant women with MSPH, the umbilical vein
dilation and endothelial NOS (eNOS) activity are reduced,
and arginase (ARG) activity is increased compared with
MPH [5, 6]. Remarkably, ARG inhibition results in a partial
restoration of human umbilical vein dilation, suggesting that
other factors play a role in this phenomenon. In nonpregnant
women, hypercholesterolemia reduces the NO bioavailability
by mechanisms that include a reduction in BH
4
levels [16].
Reduced activity and/or level of BH
4
favor(s) the generation
of a superoxide anion (O
2
∙−) instead of NO, resulting in
endothelial dysfunction [14, 17, 18]. Altogether, this indicates
that elevated plasma TCh levels may result in reduced NO
synthesis via several mechanisms, leading to endothelial
dysfunction.The potential effect ofMSPHonBH
4
availability
and regulation of the biosynthesis of this cofactor, as well
as its consequences in the modulation of fetal endothelial
function, are unknown [5, 6]. This review summarizes the
findings regarding a potential link between MSPH and BH
4
and human fetoplacental vascular endothelial dysfunction.
2. Hypercholesterolemia
In nonpregnant women, hypercholesterolemia is mainly
related to genetic mutations involving genes that are related
to cholesterol traffic, such as lipoprotein receptors and choles-
terol transporters, metabolic disorders, and an imbalanced
diet [2, 19]. According to the Third Report of the National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Choles-
terol in Adults (Adult Treatment Panel III), this condition is
the main risk factor for the development of cardiovascular
disease (CVD) [1, 2]. Therefore, the proper management of
plasma cholesterol levels can reduce the risk of developing
CVD [20]. For this reason, the clinical cut-off point for
normal blood TCh in nonpregnant women is rigorously
controlled and suggested to be <200mg/dL [1].
A higher risk of hypercholesterolemia-associated CVD
also results from a reduced blood level of high-density
lipoprotein cholesterol (HDL, i.e., <40mg/dL) and/or an
increased blood level of low-density lipoprotein cholesterol
(LDL, i.e., >100mg/dL); the latter depends on the global
cardiovascular risk, as recently recommended in the Guide-
line on the Treatment of Blood Cholesterol to Reduce
Atherosclerotic Cardiovascular Risk in Adults from the
AmericanHeart Association [21]. Although CVD is normally
diagnosed in adults, some studies indicate that endothelial
dysfunction (i.e., an initial phenomenon in the development
of atherosclerosis) and early atherosclerotic lesions (i.e., fatty
streaks) begin during intrauterine life, in fetal vessels, as
a consequence of increased levels of maternal cholesterol
[5, 6, 10]. This indicates the relevance of monitoring the
potential adverse effects of maternal cholesterolemia during
pregnancy on the fetal vasculature [22]. This is even more
important because the current global prevalence for a high
plasma concentration of TCh (>200mg/dL) in nonpregnant
women is ∼40% [23]. It is conceivable that a significant
number of pregnant womenwill have increased plasma levels
of cholesterol, exposing them to the inherent consequences
of this condition as well as the associated fetal vascular
alterations [12].
Hypercholesterolemia during Pregnancy. Pregnancy is a phys-
iological condition that is characterized by progressive weeks
of gestation-dependent increases (increasing 40–50%) in the
maternal blood level of cholesterol and triglycerides [24, 25].
MPH is considered an adaptive response of the mother to
satisfy the high cholesterol demand of the growing fetus for
membrane and hormone synthesis [26]. Unfortunately, there
are no established clinical reference values for the total and
lipoprotein cholesterol levels during pregnancy in the global
population, including the pregnant Chilean population [5,
6, 8]. A summary of the literature on the TCh, lipoprotein
cholesterol, and triglyceride concentrations per trimester of
pregnancy for different populations is shown inTable 1. Based
on the literature, the estimated mean values for TCh are 179,
226, and 257mg/dL for the 1st (1–13 weeks of pregnancy), 2nd
(14–28 weeks of pregnancy), and 3rd (28–40 weeks of preg-
nancy) trimesters of pregnancy, respectively. For HDL and
LDL, the mean values were 62 and 101, 73 and 131, and 68 and
149mg/dL for the 1st, 2nd, and 3rd trimesters of pregnancy,
respectively. MSPH has been defined by considering an at-
term cut-off point for TCh of 280–300mg/dL [5, 11, 27], and
it is associatedwith vascular alterations at birth [5] andduring
childhood [28]. Additionally, increased oxidative stress in
the maternal and fetal blood and placenta [27] as well as
reduced expression of placental LDL receptors [29]was found
in pregnancies that had maternal TCh levels that were higher
than this cut-off point.
Although lipid trafficking through the placenta is restric-
tive and children born to mothers with MSPH have normal
blood cholesterol levels [5, 31], a positive correlation between
the maternal and fetal blood cholesterol in the 2nd and
3rd trimesters of pregnancy has been established [11, 32].
Moreover, increased early atherosclerotic markers, such as
fatty streaks and lipid peroxidation, were found in the aortas
of human fetuses [11] as well as in 7- to 14-year-old children
[12] who were born to mothers with MSPH. Furthermore,
endothelial dysfunction in the human umbilical vein from
pregnancies with TCh values that were higher than this cut-
off point has been proposed to be associated with reduced
endothelium dependent vascular relaxation, due to lower
eNOS and higher ARG activity [5]. These results provide
evidence for the potential effect of MSPH in the placenta,
leading to adverse consequences for the fetal vasculature.
Interestingly, there is limited information on the prevalence
of MSPH in the global population, which is mainly because
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Table 1: Reported maternal plasma lipid concentration in pregnancy.
Studied population
(number of
pregnant women)
Trimester of
pregnancy TCh HDL LDL Tg Observations Reference
USA (142)
1
2
3
180
230
260
70
80
76
110
137
162
112
162
212
Maternal overweight and obesity
association with lipid
concentration during pregnancy
[37]
Brazil (288)
1
2
3
186
228
243
54
62
62
108
143
135
97
150
177
Maternal lipid concentration
during pregnancy as a risk factor
for GDM
[38]
Argentina (101)
1
2
3
160
201
244
58
62
61
78
107
144
90
140
202
Measurement of maternal plasma
lipids during pregnancy [39]
Chile (265)
1
2
3
178
232
269
60
73
75
102
124
147
108
179
244
Maternal lipid concentration
association with impaired
endothelium dependent dilation
of the human umbilical vein
[6]
Chile (74)
1
2
3
—
—
238
—
—
72
—
—
120
—
—
232
Cut-off point for TCh in
maternal plasma from where
fetoplacental vascular
dysfunction is seen
[5]
UK (178)
1
2
3
215
252
281
67
81
69
124
126
159
125
180
252
Measurement of maternal plasma
lipids and apolipoproteins during
pregnancy
[40]
UK (17)
1
2
3
164
212
261
—
—
—
—
—
—
77
133
233
Measurement of maternal plasma
lipids and markers of oxidative
stress in normal and GDM
pregnancies
[41]
Ireland (222)
1
2
3
197
224
278
65
75
68
104
128
147
—
—
—
Reference values for maternal
lipids during pregnancy [42]
Italy (22)
1
2
3
178
247
282
68
73
68
97
153
168
93
155
230
Measurement of maternal plasma
lipids during pregnancy [43]
Sweden (18)
1
2
3
182
238
248
69
79
69
104
140
153
99
165
215
Measurement of maternal plasma
lipids during pregnancy [44]
Spain (45)
1
2
3
166
193
228
—
—
—
—
—
—
71
106
150
Measurement of maternal plasma
LDL oxidation in normal, GDM,
and obese pregnancies
[45]
Spain (25)
1
2
3
170
234
254
68
82
71
89
136
153
60
117
184
Maternal lipases activity and
hormones concentrations during
pregnancy
[46]
Serbia (50)
1
2
3
190
245
267
75
89
79
97
126
144
85
151
219
Maternal lipid concentration
association with newborn size [47]
Turkey (801)
1
2
3
166
—
271
53
—
63
94
—
155
93
—
274
Maternal lipid concentrations
with fetal growth and
development in GDM and
preeclampsia
[48]
Israel (3938)
1
2
3
175
225
238
58
63
63
88
121
137
100
175
237
Association of maternal lipid
concentration with preeclampsia
and GDM
[49]
Nigeria (60)
1
2
3
172
203
232
41
51
63
112
126
136
93
128
171
Atherosclerotic risk in pregnant
women [50]
Women were subjected to lipids determination at 1st trimester (0–14 weeks of gestation), 2nd trimester (14–28 weeks of gestation), or 3rd trimester (28–40
weeks of gestation) of pregnancy. TCh: total cholesterol; LDL: low-density lipoprotein; HDL: high-density lipoprotein; Tg: triglycerides.—: not reported; GDM:
gestational diabetes mellitus. Values are mean in mg/dL.
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thematernal blood cholesterol level is not routinely evaluated
during pregnancy. Moreover, in a group of pregnant Chilean
women, the prevalence of this maternal condition was ∼30%
[5, 6]. As a result, a significantly higher number of pregnant
women will potentially present with an adverse intrauterine
condition that could result in the development of vascular
alterations in the growing fetus, such as endothelial dysfunc-
tion and early atherosclerosis.
3. Fetoplacental Endothelial
Dysfunction in MSPH
The placenta is a physical and metabolic barrier between the
fetal and maternal circulations, and it is a crucial organ that
supports proper fetal development [33]. Because the placenta
and umbilical cord lack autonomic innervation [34], a bal-
ance between circulating vasodilators and vasoconstrictors is
crucial tomaintaining normal fetoplacental function [33, 35].
Endothelial dysfunction is defined as an imbalance between
vasodilator and vasoconstrictor molecules that are produced
by or acting on endothelial cells [36] and that are critical for
normal fetal development.
3.1. L-Arginine/NO Pathway. NO is a gas derived from the
metabolism of L-arginine via the enzymeNOS, in ametabolic
reaction where there is equimolar generation of L-citrulline
and NO (as in the L-arginine/NO pathway) [7]. NOS are
a group of enzymes with at least three isoforms that are
encoded by different genes inmammals [57], that is, neuronal
NOS (nNOS or type 1), inducible NOS (iNOS or type 2),
and endothelial NOS (eNOS or type 3). eNOS is the main
form that is expressed in endothelial cells [3], and reduced
activity of this enzyme may result from lower expression,
reduced activation, or increased inactivation [58, 59]. eNOS
activity is modulated by different agents, including the
level of its cofactor BH
4
and posttranslational phosphory-
lation/dephosphorylation. For example, phosphorylation of
serine 1177 (Ser1177) via PI3 kinase/Akt is associated with
higher activity [60]; however, phosphorylation of threonine
495 (Thr495) via protein kinase C (PKC) maintains a low
activity of this enzyme [58, 61]. Remarkably, hypercholes-
terolemia is associated with reduced eNOS expression, an
effect that is reversed by restoring the cholesterol levels with
the use of statins, for example, [62–64]. Additionally, it has
been shown that cholesterol regulates the phosphorylation
of eNOS. In mice and pigs, there is a negative correlation
between the TCh level and the activation-phosphorylation
of Ser1177 [65, 66]. On the other hand, HDL also induces
Ser1177 phosphorylation of eNOS [67]. It was recently shown
that, in fetoplacental macrovascular endothelial cells from
pregnant women with MSPH, eNOS activity, but not its
protein abundance, is reduced [5]. However, Ser1177and
Thr495phosphorylation was reduced compared to cells from
pregnant women with MPH. As a result, an altered maternal
cholesterol level may modify the eNOS activity in pregnancy.
3.2. ARGs/Urea Pathway. ARGs (ARG-I and ARG-II) are a
family of enzymes that compete with NOS for the substrate
L-arginine, leading to the synthesis of L-ornithine and urea
[68]. Interestingly, hypercholesterolemia is associated with
increased ARG activity in animal models [69, 70] and
humans [71, 72]. The activity of ARGs is also increased
in HUVECs from pregnancies with MSPH compared with
MPHpregnancies [5]. Because the pharmacological blockade
of ARG with S-(2-boronoetil)-L-cysteine (BEC) partially
reverses the reduced eNOS activity observed in HUVECs in
MSPH pregnancies, ARGs are likely involved in modulating
eNOS activity in this cell type [4].
4. BH4 Metabolism in MSPH
4.1. BH4. BH4 is a cofactor required for NOS activity because
this molecule stabilizes the enzyme as an active dimer,
allowing for optimal oxidation of L-arginine into NO [13,
15]. A reduction in the BH
4
level leads to reduced eNOS
activation, which is likely due to the uncoupling that results
in the generation of superoxide anion (O
2
∙−) rather than
NO, promoting vascular oxidative stress and endothelial
dysfunction [14]. In the endothelium, BH
4
is synthesized
by at least two metabolic pathways: de novo biosynthesis
from guanosine triphosphate (GTP) and the salvage pathway
from sepiapterin to BH
2
and BH
4
[14] (Figure 1(a)). De novo
biosynthesis involves the sequential action of GTP cyclo-
hydrolase 1 (GTPCH1), 6-piruvoil tetrahydropterin synthase
(PTPS), and sepiapterin reductase (SR). The GTPCH1 step is
the limiting step of the pathway, and it is highly regulated at
the transcriptional, translational, and posttranslational levels
[73]. For the salvage pathway, the reduction of BH
2
to BH
4
is the limiting step and requires the enzyme dihydrofolate
reductase (DHFR) [73]. The BH
4
level could be reduced by
decreased synthesis and by the oxidation of BH
4
to BH
2
via
oxygen-derived reactive species and peroxynitrite (ONOO−),
resulting in eNOS uncoupling (Figure 1(b)) [13, 18, 74]. The
latter is a phenomenon that occurs in a variety of clinical
conditions that are associatedwith vascular disease, including
diabetes mellitus, hypertension, atherosclerosis [75–77], and
hyperglycemia [18].
4.2. BH4 Metabolism in Hypercholesterolemia. Patients with
hypercholesterolemia have lowNOavailability [78, 79] aswell
as a lower BH
4
level (Table 2). Interestingly, oral or local sup-
plementation with BH
4
restores the impaired NO-dependent
vasodilation in subjects with hypercholesterolemia [13, 52, 55,
80]. The association between human hypercholesterolemia
and a reduced level of GTPCH1 has not yet been addressed
[14, 18]. However, reduced eNOS activity is reversed by
supplementation with the BH
4
substrate sepiapterin or by
GTPCH1 overexpression in mice [81–83]. As a result, this
enzyme likely plays a role in hypercholesterolemia. Incuba-
tion with human LDL reduces NOS and GTPCH1 expression
in rat vascular smooth muscle cells [84, 85]. Additionally, a
reduced level of GTPCH1 due to hyperglycemia in human
aortic endothelial cells decreases the BH
4
level and NO
synthesis, which is reversed by GTPCH1 overexpression
[86]. Interestingly, and in corroboration with these findings,
there are results showing similar changes in HUVECs that
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GTP
GTPCHI
Tetrahydrobiopterin 7,8-Dihydrobiopterin
Oxidative stress
Sepiapterin
Salvage pathwaySynthesis de novo
DHFR
SR
(BH4) (BH2)
(a)
eNOS
NO
L-arginine
L-citrulline
L-arginine
L-citrulline
Coupled NOS Uncoupled NOS
BH4 BH2
O2
∙−
(b)
Figure 1: Tetrahydrobiopterin metabolism and endothelial nitric oxide synthase uncoupling. (a) The first step in the de novo synthesis of
tetrahydrobiopterin (BH
4
) is the rate limiting reaction involving the enzyme GTP cyclohydrolase 1 (GTPCH1), whose substrate is GTP. An
alternative salvage pathway for BH
4
synthesis is the reduction of 7,8-dihydrobiopterin (BH
2
) to BH
4
by the enzyme dihydrofolate reductase
(DHFR). BH
2
is generated from sepiapterin by the sepiapterin reductase enzyme (SR).Oxidative stressmaybe an environmental condition that
promotes the oxidation of BH
4
to BH
2
, decreasing the bioavailability of BH
4
. (b) Under physiological conditions, nitric oxide synthases (NOS,
coupled NOS) generate nitric oxide, following the metabolism of L-arginine into L-citrulline in the presence of BH
4
. However, uncoupling
NOS (uncoupled eNOS) with these enzymes may result in the generation of a superoxide anion (O
2
∙−). This phenomenon results from a
deficiency in BH
4
and an increased BH
2
bioavailability (from data in [6, 17, 30]).
were subjected to the pharmacological induction of GTPCH1
expression [87].
The potential effect of MSPH on BH
4
availability in the
regulation of the synthesis of this cofactor and its effect on the
modulation of fetal endothelial function are unknown [5, 6].
Because NO synthesis is reduced in the fetal endothelium
from pregnancies with MSPH via mechanisms involving
increased ARG but reduced eNOS activity, it is hypothesized
that this maternal condition could also result in reduced BH
4
bioavailability for NO synthesis. As a result, these potential
mechanisms could explain the endothelial dysfunction and
reduced vascular relaxation observed in MSPH. Preliminary
results show that the BH
4
level is reduced in HUVECs from
MSPH [88] (Leiva A., Sobrevia L., unpublished). However,
it is unknown whether BH
4
metabolism is altered in human
fetoplacental endothelial cells in pregnancies with MSPH or
whether restoration of the BH
4
level improves the endothelial
dysfunction in MSPH [4–6, 33].
5. Concluding Remarks
The prevalence of MSPH in the global population has not
been evaluated, although it is estimated as approximately
30% [5, 6]. MSPH is a factor that favors the development
of vascular changes in the growing fetus and, eventually, in
children [12]. These vascular disorders include endothelial
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Table 2: Effect of hypercholesterolemia on tetrahydrobiopterin availability and endothelial function.
Study model Tissue or cell type Experimentalcondition BH4 level Parameter Effect
Reference
Hypercholesterolemia Human brachialartery
Basal Reduced Endothelium dependentvasodilation Reduced [13]
BH
4
infusion Increased Endothelium dependentvasodilation Increased
Hypercholesterolemia Human coronaryartery
Basal Reduced Coronary arterydiameter and flow Reduced [51]
BH
4
infusion Increased Coronary arterydiameter and flow Increased
Hypercholesterolemia Human brachialartery
Basal Reduced Endothelium dependentvasodilation Reduced [52]
BH
4
supplementation Increased Endothelium dependentvasodilation Increased
Hypercholesterolemia
Human coronary
microcirculation
Basal nr Myocardial blood flow Reduced
[53]BH
4
infusion nr Myocardial blood flow Increased
Hypercholesterolemia Human skin
Basal nr Endothelium dependentvasodilation Reduced
[54]R-BH
4
infusion nr Endothelium dependentvasodilation Increased
S-BH
4
infusion nr Endothelium dependentvasodilation Reduced
Hypercholesterolemia Human skin
Basal nr Endothelium dependentvasodilation Reduced [55]
BH
4
infusion nr Endothelium dependentvasodilation Increased
Cell culture
Human mesenteric
microvascular
endothelial cells
Incubation with
oxLDL
Reduced NO generation Reduced
[56]Reduced Superoxide generation Increased
Incubation with
oxLDL + sepiapterin
Increased NO generation Increased
Increased Superoxide generation Reduced
Cell culture Human aorticendothelial cells
Incubation with LDL Reduced NO generation Reduced
[52]Incubation with LDL
+ BH
4
nr NO generation Increased
Basal corresponds to no treatment. BH4: tetrahydrobiopterin; R-BH4: R-tetrahydrobiopterin (NO synthase cofactor and antioxidant); S-BH4: stereoisomer of
BH4 (antioxidant); oxLDL: oxidized low-density lipoprotein; LDL: low-density lipoprotein; NO: nitric oxide; nr: not reported.
dysfunction in the fetus and placenta, disrupting the equili-
bration between the ARG/urea and L-arginine/NO signaling
pathways. However, it is unknown whether these alterations
correlate with the degree of MSPH in pregnancy or the
alterations in BH
4
metabolism and eNOS function (Figure 2).
Drugs that control the TCh plasma level in adult, nonpreg-
nant subjects are not used during pregnancy. This condi-
tion limits our present knowledge regarding the correlation
between the mother’s and fetus’s TCh level and the vascular
function of the fetus during pregnancy. However, based
on the available evidence from subjects with hypercholes-
terolemia, we propose that restoration of the BH
4
level will
improve the fetoplacental endothelial function in humans.
Therefore, it is essential to focus future studies on exploring
the dynamics of the BH
4
metabolism in MSPH pregnancies
and the possible contribution that restoring this cofactor
could have on this maternal condition and vascular function.
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